[
  {
    "id": "62-pleural-tb-ocr-complete--1--chunk-0",
    "bookId": "62-pleural-tb-ocr-complete--1-",
    "sectionTitle": "Epidemiology",
    "content": "<!-- Page 1 -->\n\nTUBERCULOUS PLEURAL EFFUSION\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 2 -->\n\n*   MCC **exudative pleural effusion** in our country.\n    *   ! Pleural TB > LNTB?\n*   **Lymph nodes** are the most common extrapulmonary site (33%) involved, **pleural involvement** is the second most common.\n\n\n\n### Epidemiology\n\n*   MC Affected **younger age groups (20-40 years)**\n*   A higher incidence in **diabetic** population.\n\nDR. BHARATH KATHI MD DNB FIP FADI EDARM\n\n---\n\n<!-- Page 3 -->\n\n\n\n# Pathophysiology\n\n*   Immunological factors:\n    *   Delayed hypersensitivity type phenomenon due to the [TEXT OBSCURED]\n    *   [TEXT OBSCURED].\n*   Contiguous spread from lung\n*   Haematogenous and lymphatic spread\n\n---\n*(Handwritten note on yellow sticky note)*\nRupture of subpleural foci\n↓\nEntry of mycobacteria into pleural space\n- contiguous spread\n\n---\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 4 -->\n\n1.  Rupture of subpleural foci with the entry of mycobacterial Ag into the pleural space\n2.  inflammation, increased capillary permeability, and generation of pleural fluid.\n3.  Increased PMN leucocytes peaks at 3 -4 days.\n    Effusion lymphocyte predominance emerges followed by influx of macrophages\n4.  TH 1 cells mediate this robust immune response entailing a delayed type hypersensitivity response to MTB with release of releases ADA & INF GAMMA\n\n*   Granuloma formation to prevent <u>further dissemination</u>\n*   Bacteria rapidly cleared d/t robust immune response hence <u>paucibacillary</u> tubercular effusion.\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 5 -->\n\n\n\n# >Clinical H/O & EXAMINATION\n\n*   Most common clinical symptom : cough (94% of patients)\n\n\n\n## HISTORY\n\n*   Fever (circled)\n*   Pleuritic chest pain (checked)\n*   Cough (checked)\n*   Breathlessness (checked)\n*   Anorexia }\n*   Weight loss } (Anorexia and Weight loss are bracketed together)\n*   History of TB contact\n\n\n\n## EXAMINATION\n\n*   \\*\n*   Dullness to percussion\n*   Decreased/absent\n*   breath sound (circled)\n\n\n\n## Associated Symptoms (from images)\n\n*   FEVER\n*   CHEST PAIN\n*   CHILLS\n*   WEIGHT LOSS\n*   FATIGUE\n*   NIGHT SWEATS\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 6 -->\n\n\n\n# WHAT TESTS ?\n\n\n\n## ALL\n*   CXR\n*   HIV Testing\n*   Thoracentesis\n\n\n\n## Selected\n*   CT chest & abdomen\n*   USG Chest ! Thoracentesis\n*   Sputum samples\n*   Pleural biopsy\n*   NAAT ( Can be considered if available )\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 7 -->\n\n\n\n# Investigations\n\n\n\n## ESSENTIAL\n*   CXR (to confirm pleural effusion)\n*   Sputum for AFB/NAAT\n*   Refer immediately for pleural tap\n*   Thoracentesis (ultrasound-assisted)\n*   Pleural fluid analysis:\n    *   Cell count (total and differential)\n    *   Protein\n    *   Glucose\n    *   Gram stain\n    *   Bacterial cultures\n    *   Stain for acid-fast bacilli\n    *   Adenosine deaminase (ADA)\n    *   NAAT\n    *   Cytology evaluation\n\n\n\n## DESIRABLE\n*   CT chest (before pleural biopsy)\n*   Pleural biopsy (image-guided/thoracoscopic) (If diagnosis is uncertain)\n*   Histopathology\n*   MGIT\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 8 -->\n\n\n\n# Sample Collection And Transport:\n\n*   As soon as possible ⚡ Maximum accepted time delay for the pleural fluid sample is 2 hours, can be stored for up to 48 hours at 4 deg C for most tests except for microbiological culture.\n*   For long term storage, sample centrifuged and stored at -80deg c. ❌\n*   Samples can be viable for protein, LDH and ADA for at least for a few years and for cytokines up to 45 days. ✔️\n*   Recommendations: EPTD module\n\n| Test/Analysis                               | Volume/Container                                          |\n| :------------------------------------------ | :-------------------------------------------------------- |\n| Cell counts                                 | 3-4ml in an anti-coagulant coated tube. (EDTA/heparin) |\n| Microbiological analysis (gram stain and NAAT) | 2-5ml                                                     |\n| Aerobic and anaerobic culture media         | 2-5ml                                                     |\n| liquid culture media for M. tuberculosis.   | 5ml                                                       |\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 9 -->\n\n\n\n# Pleural Fluid Analysis\n\nThe first line investigations to be sent are:\n*   Cell count – total count/differential count\n*   Protein ≈ Exudate\n*   Glucose\n*   ADA\n\nOther:\nIFNγ > 140 pg/ml\n\nPleural fluid examination for the diagnosis of pleural tuberculosis\n\n| Pleural Fluid                  | Frequency     |\n| :----------------------------- | :------------ |\n| Exudate with protein >3g/dL    | Almost all (7) |\n| Pleural fluid glucose >60mg/dL | 80-85% (8)    |\n| >50% lymphocytes               | 93.3% (8)     |\n| Pleural fluid ADA >40 IU/L     | 81-100% (22)  |\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 10 -->\n\n\n\n## Adenosine deaminase (ADA):\n\n*   semi-specific biochemical marker for diagnosis with a cut off level of 40 IU/l.\n*   sensitivity of 92% and a specificity of 90%.\n\n| Level        | Interpretation                                                          |\n| :----------- | :---------------------------------------------------------------------- |\n| 70 IU/L      | Highly likely to be pleural TB ✓                                        |\n| 40-70 IU/L   | Indeterminate level, other risk factors to be considered Suspect ✓      |\n| <40 U/L      | Low likelihood of TB, investigate for other causes ✓                    |\n\n**OTHER DIAGNOSTIC MARKERS AND TESTS :**\nINTERFERON GAMMA X\nINTERFERON GAMMA RELEASE ASSAY X\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 11 -->\n\n\n\n# ALGORITHM\n\n\n\n## Pleural effusion\n\n1.  Sputum examination and thoracentesis\n    *   **Sputum or pleural fluid positive for AFB or NAAT?**\n        *   **Yes**: Start anti-TB treatment\n        *   **No**: Pleural fluid ADA\n            *   **< 40 U/L**\n                *   Pleural biopsy\n                *   Treat based on results of biopsy and microbiological examination\n            *   **40-69 U/L**\n                *   *(Handwritten note: Reevaluate after 1 month)*\n                *   **Age <40 years, fever, non-smoker, alternate etiology unlikely?**\n                    *   **Yes**: Initiate empiric anti-TB therapy\n                        *   If no response in 4 weeks\n                    *   **No**: Pleural biopsy (arrow points back to this step)\n            *   **≥ 70 U/L**\n                *   Initiate empiric anti-TB therapy\n\n---\n\n<!-- Page 12 -->\n\n\n\n# Diagnostic yield\n\n| Test/Method | Diagnostic Yield |\n|---|---|\n| Plef ZN Stain | Very low (10-20%) |\n| Plef Culture | 12-30 % (*) |\n| Plef NAAT | 49.5 % (✓✓) |\n| NAAT on pleural biopsy | 45-85.5% (* Best) |\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n12\n\n---\n\n<!-- Page 13 -->\n\n\n\n## WHICH BIOPSY METHOD ?\n*Thoracoscopic Dx + Bx*\n\nPatients with exudative pleural effusion with inconclusive initial workup have the option of undergoing thoracoscopy or a percutaneous pleural biopsy.\n\nWhile the yield of thoracoscopy has been found to be higher in such scenarios (93.2% vs 84.5% for percutaneous pleural biopsy), the cost and availability remain major issues. *\n\n✓ A combination of ADA, lymphocytic predominance with closed needle biopsy has shown to have a sensitivity of nearly 93% and around 100% specificity.\n\n⭐ More than 6 biopsy specimens should be taken in suspected tuberculous pleural effusion to maximize yield.\n\nHistopathology with evaluation for the presence of granulomas has a sensitivity of 72-80% in diagnosing tuberculosis while the use of culture in these specimens has a sensitivity of 60-67%.\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 14 -->\n\n\n\n# TB PLEF MANAGEMENT\n\n*   **ATT : 2HRZE + 4HRE**\n    (Total: 6 Months)\n*   **Pleural Fluid Drainage:**\n    If the effusion is causing\n    **respiratory distress**\n    (SOB, increase in\n    respiratory rate)\n*   **Nutritional Management**\n    protein +\n    calories\n*   **? Steroids**\n*   **Managing complications**\n\n---\n\n*   Recent meta-analysis: Steroids might reduce the time to resolution of effusion and decrease the risk of chronic pleural changes (thickening/adhesions), there was no evidence to show difference in long term respiratory function (so not recommended routinely) ? risk of adverse events.\n*   In view of very low mortality in pleural tuberculosis and insufficient data corticosteroids are not recommended for the treatment of pleural tuberculosis.\n\n---\n\n<!-- Page 15 -->\n\n\n\n# Complications:\nA. Lack Of Response:\n*   Continuation of symptoms such as fever, **loss of appetite and SOB after 2 months of** therapy must be further investigated.\n*   After ensuring **drug adherence and no interactions with other drugs being taken** the following possibilities must be considered:\n    *   Immune reconstitution inflammatory syndrome (IRIS) (handwritten check, then cross, then ??)\n    *   Drug Resistance (handwritten check, then cross)\n    *   Alternate diagnosis: (handwritten check)\n        *   Superadded infection (handwritten check)\n\n\n\n# Differentials\n(i) Malignant pleural effusion (handwritten cross, then check)\n(ii) Empyema (handwritten cross)\n(iii) Fungal related effusion (handwritten cross, then check)\n(iv) Chylothorax (handwritten cross)\n(v) Hemothorax (handwritten cross)\n(vi) Liver abscess (handwritten cross)\n(vii) Sarcoidosis (handwritten cross, then check)\n(viii) SLE/Rheumatoid pleurisy (handwritten cross, then check)\n(ix) Viral pneumonia (influenza, COVID-19 etc.)\n\nB. Pleural thickening (handwritten cross, then check)\nC. Empyema (handwritten cross, then check)\nD. Hydropneumothorax (handwritten underline)\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 16 -->",
    "wordCount": 1413,
    "index": 0,
    "subTopicId": "1766794361908-fbjb5jx96"
  },
  {
    "id": "62-pleural-tb-ocr-complete--1--chunk-1",
    "bookId": "62-pleural-tb-ocr-complete--1-",
    "sectionTitle": "Follow up & duration",
    "content": "# Follow up & duration\n\n*   Initial improvement in 2 weeks, significant improvement in 4-8 Weeks\n*   Follow up CXR at 4-8 weeks to assess\n\nDR. BHARATH KATHI MD DNB FIP KADI BOARD\n\n---\n\n<!-- Page 17 -->\n\nTable 1: Treatment duration of medical therapy in extrapulmonary Tuberculosis.\n\n| Site of Disease                 | Initial Regimen (IP + CP) | Duration      |\n| :------------------------------ | :------------------------ | :------------ |\n| Ocular TB                       | (2)HRZE + (4-7)HRE        | 6-9 Months    |\n| CNS TB                          | (2)HRZ+E/S + (10)HRE      | 6-12 Months (✓) |\n| Tuberculous Otitis Media        | (2)HRZE + (7)HRE          | 9 Months      |\n| Ear, Nose and Throat TB (Others)| (2)HRZE + (4-7)HRE        | 6-9 Months    |\n| Lymph node TB                   | (2)HRZE + (4-7)HRE        | 6-9 Months    |\n| Pleural TB                      | (2)HRZE + (4)HRE          | 6 Months (~~*~~) |\n| Pericardial TB                  | (2)HRZE + (4)HRE          | 6 Months      |\n| *Hepatobiliary TB               | (2)HRZE+(4-7)HRE          | 6-9 Months    |\n| Intestinal TB                   | (2)HRZE + (4)HRE          | 6 Months      |\n| Urinary TB                      | (2)HRZE + (4)HRE          | 6 Months      |\n| Genital TB (Male or Female)     | (2)HRZE + (4)HRE          | 6 Months      |\n| Spinal TB                       | (2)HRZE + (10-16)HRE      | 12-18 Months  |\n| Bone and Joint TB (others)      | (2)HRZE + (10)HRE         | 12 Months     |\n| Cutaneous TB                    | (2)HRZE + (4)HRE          | 6 Months      |\n\nH - Isoniazid, R - Rifampicin, Z - Pyrazinamide, E - Ethambutol, S - Streptomycin, Amikacin\n*Treatment may be modified according to stage of Liver Disease. Refer below\n\nTraining Module On Extrapulmonary Tuberculosis 2023\n\nHandwritten notes:\nSee next page simplified\n\n---\n\n<!-- Page 18 -->\n\nThe table describes treatment durations and regimens for various extrapulmonary tuberculosis (TB) sites.\n\n**Treatment Duration of Medical Therapy in Extrapulmonary TB**",
    "wordCount": 299,
    "index": 1,
    "subTopicId": "1766794361908-fbjb5jx96"
  },
  {
    "id": "62-pleural-tb-ocr-complete--1--chunk-2",
    "bookId": "62-pleural-tb-ocr-complete--1-",
    "sectionTitle": "| Duration (months) | Regimen           | Site of",
    "content": "| Duration (months) | Regimen           | Site of Disease",
    "wordCount": 9,
    "index": 2,
    "subTopicId": "1766794361908-fbjb5jx96"
  },
  {
    "id": "62-pleural-tb-ocr-complete--1--chunk-3",
    "bookId": "62-pleural-tb-ocr-complete--1-",
    "sectionTitle": "---",
    "content": "---\n\n<!-- Page 19 -->",
    "wordCount": 5,
    "index": 3,
    "subTopicId": "1766794361908-fbjb5jx96"
  },
  {
    "id": "62-pleural-tb-ocr-complete--1--chunk-4",
    "bookId": "62-pleural-tb-ocr-complete--1-",
    "sectionTitle": "Drug dosages for first-line anti- TB drugs",
    "content": "### Drug dosages for first-line anti- TB drugs\n\n| Drugs             | Doses                                |\n| :---------------- | :----------------------------------- |\n| Isoniazid (H)     | 5 mg/kg daily (4 to 6 mg/kg)         |\n| Rifampicin (R)    | 10 mg/kg daily (8 to 12 mg/kg)       |\n| Pyrazinamide (Z)  | 25 mg/kg daily (20 to 30 mg/kg)      |\n| Ethambutol (E)    | 15 mg/kg daily (12 to 18 mg/kg)      |\n| Streptomycin (S)\\* | 15 mg/kg daily (15 to 20 mg/kg)      |\n\n\\*Streptomycin is administered only in certain situations, like TB meningitis or if any first line drug need to be replaced due to ADR as per weight of the patient\n\nPyridoxine may be given at a dosage of 10 mg per day\n\n\n\n### Number of tablets (FDCs)\n\n| Weight category | Intensive Phase H: 75mg; R: 150 mg; Z: 400 mg; E: 275 mg) | Continuation Phase H: 75mg; R: 150 mg; E: 275 mg) |\n| :-------------- | :------------------------------------------------------- | :------------------------------------------------ |\n| 25 to 34 kg     | 2                                                        | 2                                                 |\n| 35 to 49 kg     | 3                                                        | 3                                                 |\n| 50 to 64 kg     | 4                                                        | 4                                                 |\n| 65 to 75 kg     | 5                                                        | 5                                                 |\n| >75 kg          | 6 (~5)                                                   | 6                                                 |\n\n*   Fixed Dose Combinations (FDCs) refer to products containing two or more active ingredients in fixed doses, used for a particular indication(s)\n*   In NTEP, for Adults: 4-FDC (given in IP) consists of HRZE and 3-FDC (given in CP) consists of HRE\n*   During treatment if weight of the patient increases by > 5 kg and crosses the next weight band then patient should be given the next higher weight band FDC drugs\n\n---\n\n<!-- Page 20 -->\n\n\n\n# Standard Treatment Workflow (STW) Guidelines for\n\n\n## DRUG SENSITIVE-TB TREATMENT AS PER NTEP\n\n| Regimen for DS-TB | IP    | CP    |\n| :---------------- | :---- | :---- |\n| Drugs             | 2 HRZE | 4 HRE |\n| Doses             | 56    | 112   |\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 21 -->\n\nTable 11.2. Sensitivity and specificity of microbiological tests in extrapulmonary TB specimens\n\n| Extrapulmonary Samples | ZN Staining | | Culture (MGIT/LJ) | | NAAT | |\n|---|---|---|---|---|---|---|\n| | Sensitivity | Specificity | Sensitivity | Specificity | Sensitivity | Specificity |\n|---|---|---|---|---|---|---|\n| Cerebrospinal fluid | 12.5%-69% | | 25-70% | | 71% | 97% |\n| Lymph node | ~50% | >90% | | | [Redacted] | 96% |\n| Pleural fluid | Very low | | 12-30% | | [Redacted] | 99% |\n| Synovial fluid | | | | 99% | [Redacted] | 64% |\n| Bone biopsy | 25-75% | | 50-55% | | [Redacted] | 95-98% |\n| Liver biopsy | 0-45% | | 0-43% | | 88% | 100% |\n| Intestinal biopsy | 2.7-37.5% | | ~50% | | 32% | 100% |\n| Urine | very low | | 10.7-80% | | 87% | 91% |\n\n---",
    "wordCount": 502,
    "index": 4,
    "subTopicId": "1766794361908-fbjb5jx96"
  }
]